Severe case of pneumonia with pleural effusion in an immunocompromised woman due to Fusobacterium necrophorum

Infections caused by fusobacteria have a wide clinical spectrum, and in certain patients, they can lead to severe systemic illness. We report the case of an immunocompromised young woman who presented with severe pneumonia complicated by parapneumonic pleural effusion, despite wide-spectrum antibiotic treatment. Fusobacterium necrophorum was isolated in the samples obtained after thoracentesis was performed. Apart from the pulmonary involvement, we could not identify the infectious focus, since the patient did not have poor dentition or Lemierre's syndrome. After an extended antibiotic regimen and placement of a chest tube, the patient fully recovered and was able to be discharged.

http://bit.ly/2t0VQga

Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy

Erythrodermic psoriasis (EP) is the most serious type of psoriasis with high morbidity and mortality. First-line recommended therapies for EP, cyclosporine and infliximab have significant adverse effects. Cyclosporine increases the risk of hypertension, leucopenia, infections and renal failure. Infliximab increases the risk of reactivation of tuberculosis, hepatitis B and histoplasmosis, and increases risk for hepatitis, autoantibody formation, congestive heart failure, demyelinating disorders, pancytopenia, lymphoma and skin cancer. An effective drug with a much safer side effect profile will be of significant benefit in EP. The phosphodiesterase 4 inhibitor apremilast is U.S Food and Drug Administration (FDA) approved for plaque psoriasis and psoriatic arthritis. Adverse effects of apremilast reported are headache, nausea, diarrhoea, upper respiratory tract infection, potential for depression and weight loss. We report complete and long-standing resolution of EP with first-line apremilast monotherapy. Apremilast may be an effective option with comparatively minor side effects for EP.

http://bit.ly/2HHaaVm

Ectopic varices masquerading as lower gastrointestinal bleeding

A middle-aged woman previously in good health arrived to hospital with severe haemorrhagic shock. An abdominal and pelvic CT scan showed hepatomegaly, fluid in the sigmoid colon, perigastric and right sided pelvic varices without a clear source of bleeding. Urgent esophagogastroduodenoscopy excluded gastric varices and active upper gastrointestinal bleeding and the colonoscopy was inconclusive due to haemodynamic instability and massive bleeding which made it impossible to proceed with a full colonoscopy. An explorative laparotomy identified liver cirrhosis and bleeding from varices of the right fallopian tube which had formed a fistula with the caecum. A right hemicolectomy with a side to side anastomosis and a right sided salpingo-oophorectomy were carried out. The patient was thereafter transferred to the intensive care unit intubated, requiring massive fluid resuscitation and high doses of vasoactive agents. Nine days after hospital admission she was transferred to the surgical ward and followed up by a hepatologist.

http://bit.ly/2t1RfKR

Adipsic diabetes insipidus secondary to craniopharyngioma resection

Adipsic diabetes insipidus is an infrequent disease which may be associated with craniopharyngioma. It may be secondary to the tumour's extension, as well as to resection of the mass. We present the case of a 24-year-old woman with a history of delayed puberty and hypothyroidism, but no prior study reports. She consulted due to a headache with warning signs associated with altered visual acuity. Brain MRI was performed which showed signs of a non-adenomatous lesion with suprasellar and hypothalamic extension. Following transcranial surgery, she developed diabetes insipidus criteria, with absence of thirst documented during the hospitalisation. The histopathological findings confirmed the diagnosis of craniopharyngioma. The patient was treated with desmopressin and received recommendations regarding rehydration according to the quantification of losses, with electrolyte stabilisation.

http://bit.ly/2HLvo4t

Rare cause of lung atelectasis in a young woman

Pulmonary mucoepidermoid carcinoma is an extremely rare intrathoracic malignancy, comprising less than 1% of all lung tumours. These are very slow growing and are classified into low grade and high grade based on histological features. Surgical resection is the primary treatment with excellent outcomes, while chemotherapy or radiotherapy effectiveness is not known. Preoperative fluorine-18 fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) is useful for predicting tumour grade and postsurgical prognosis.

A clinical case of a 31-year-old woman who presented with dyspnoea on exertion, cough and wheezing is reported. Imaging studies revealed a mass involving the left lower lobe bronchus and atelectasis. 18F-FDG PET/CT showed uptake in the described mass with a maximum standardised uptake value of 9.7. Complete surgical resection was performed, and pathological examination revealed a high-grade mucoepidermoid carcinoma with tumour-free margins. Adjuvant chemotherapy was given and there is no evidence of tumour recurrence.

http://bit.ly/2HICtmd

Stickler syndrome: a possible presentation of Pierre Robin sequence

http://bit.ly/2t0VOF4

Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma

It is unknown whether tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) can be discontinued in patients in whom EGFR-mutated lung cancer has well stabilised. We present a case of a 73-year-old Japanese woman with no history of smoking. Right pulmonary lower lobectomy, lymph node dissection and segmental resection of the right middle lobe were performed. Additionally, she underwent adjuvant chemotherapy for stage IIIB adenocarcinoma harbouring an EGFR exon 19 deletion. Afatinib was administered for liver metastases after 15 months. A complete response of metastatic disease was achieved for 2 years. However, afatinib was unavoidably discontinued due to splenectomy for the treatment of idiopathic thrombocytopenic purpura. Although afatinib was not resumed, due to the abscess formation as surgery complication, a drug-free complete response was sustained for over 18 months. The present case suggests that exceptional and durable responses to afatinib can be achieved in individual cases.

http://bit.ly/2HK9YEY

Seizure in infancy: not the usual suspect

http://bit.ly/2sWcAVW

'Never say never: the first successful management of a type A aortic dissection in Liberia

The West African country of Liberia ranks as one of the lowest in the world in most measures of health. The diagnosis and management of complex surgical cases such as aortic dissection is extremely challenging, for reasons ranging from lack of diagnostic imaging capabilities to the high resources required for definitive surgical intervention. We present the first known successfully managed case of aortic dissection in the country's history and with it highlight the challenges faced and a number of lessons learned that are beneficial to anyone working in resource-limited environments.

http://bit.ly/2HEE7W2

A tale of 1 year: a case of bilateral conductive hearing loss due to bilateral ossicular chain disruption post head trauma

Abstract

The traumatic hearing loss is a common finding after head trauma that involves the temporal bone fracture or skull base injury, but the late presentation of the hearing loss bilaterally is a rare presentation. This case report describes the rare and late presentation of bilateral conductive hearing loss 1-year after the head trauma, limited to ossicular chain disruption and hearing loss. This case of post head trauma that was limited to ossicular chain distribution progressed to bilateral conductive hearing loss without temporal bone fracture. A 14-year-old male was presented conductive hearing loss of one year after head injury, CT scan revealed bilateral ossicles disruption. Afterwards, osicuoloplasty was performed which improved the hearing of the patient. In conclusion, bilateral hearing loss with no obvious skull fracture should be suspected and investigated so an early intervention could be established. The CT was considered the imaging modality of choice for ossicular chain distribution.

http://bit.ly/2BffZnh

Proceed or palliate: Surgicel® mimicking tumor recurrence and causing a small bowel obstruction

Abstract

Surgicel® is a commonly used hemostatic agent. We report a case of small bowel obstruction secondary to the prior placement of Surgicel® within the peritoneal cavity, and the radiological diagnosis conundrum and potential prognostic implications this finding has in a patient with a known history of malignancy.

http://bit.ly/2TjYp8G

Unclassified autoimmune pancreatitis mimicking pancreatic cancer

Abstract

A 24-year-old black male presented with a 1-week obstructive jaundice and intermittent abdominal pain, with no significant weight loss and an unsuspicious abdominal exam. Blood chemistry showed a cholestatic pattern but a complete immunological and tumoral panel (anti-smooth muscle antibody, anti-mitochondrial antibody, anti-nuclear antibody, anti-neutrophil cytoplasmic antibody, anti-Smith, anti-double-stranded-DNA antibody (anti-dsDNA), complement C3/C4, carcinoembryonic antigen, CA 19-9 and IgG4) were all within normal limits. Abdominal ultrasound revealed dilatation of the intra and extra-hepatic bile ducts. CT scan showed an abnormal dilatation of the distal bile duct but no focal enlargement of the head of the pancreas. Endoscopic ultrasound suggested an inflammatory process but the magnetic resonance cholangio-pancreatography favored a neoplastic obstruction of the distal common bile duct. Fine-needle aspiration cytology was insufficient for definitive diagnosis and the patient underwent major surgery. Follow-up with mild exocrine pancreatic insufficiency treated with enzyme replacement.

http://bit.ly/2BgqeYx

Combination of laparoscopy and endoscopy as an option for treatment patients with gastric neuroendocrine tumors

Abstract

Background

Neuroendocrine tumors (NETs) are relatively rare neoplasms with the increasing survival due to the development of early diagnostics. There is no universal position in treatment and follow up of small (~20 mm) gastric NETs.

Clinical cases

Two female patients 51 and 66 y.o. with multiple gastric NETs <2 cm were observed in our department. In both cases treatment was performed by combination of two minimally invasive technologies: laparoscopy and gastroscopy. According to the localization of tumors in one case intraluminal gastric resection controlled by laparoscopy was performed. In the second case laparoscopic gastric resection with gastroscopy assistance was done.

Discussion

There are two positions for surgical treatment of small NETs: to operate as the typical premalignant neoplasm or to make submucosa resections. We demonstrated combination of laparoscopy and gastroscopy as feasible approach with minimal risk of complications.

http://bit.ly/2Tnkfbl

Small bowel intussusception and concurrent sigmoid polyp with malignant transformation in Peutz–Jeghers syndrome

Abstract

Peutz–Jeghers syndrome (PJS) is an autosomal dominant condition characterized by the association of gastrointestinal polyposis, mucocutaneous pigmentation and cancer predisposition McGarrity, Amos, Baker (Peutz–Jeghers Syndrome, GeneReviews(R), National Center of Biotechnology Information.). Intussusception and malignant polyps are not rare complications of PJS, where the lifetime risk of intussusception is 48% and the possibility of developing any cancer by age 65 years is 37% Kopacova, Tacheci, Rejchrt, Bures (Peutz-Jeghers syndrome: diagnostic and therapeutic approach. World J Gastroenterol 2009;15:5397–408.). Very few cases of malignant polyps causing intussusception associated with synchronous malignant polyp in PJS have been reported to date Cai, Tian, Zhou, He, Hu, Deng (Jejunal intussusception and polyps with different types of malignant transformation in Peutz-Jeghers syndrome: report of a case. Oncol Lett 2013;5:239–41.). We describe a case of a patient with PJS presenting with symptomatic jejunal intussusception and an incidentally found malignant hamartoma in the sigmoid colon.

http://bit.ly/2Bgqcjn

Coexistence of intracranial solitary fibrous tumor/hemangiopericytoma and right middle cerebral artery aneurysm

Abstract

Intracranial solitary fibrous tumors are rare mesenchymal neoplasms originating in the meninges and constitute a heterogeneous group of rare spindle cell tumors that include benign and malignant neoplasms of which hemangiopericytoma is nowadays considered a cellular phenotypic variant. From literatures, the incidence of coexistence of brain tumors and intracranial aneurysms is ~0.7–5.4%. Meningioma is the most frequent tumor coexisted with intracranial aneurysms, followed by pituitary adenoma, neuroepithelial tumor, and metastatic tumor. We would like to report a case of 74-year-old man harboring a rare intracranial solitary fibrous tumor/hemangiopericytoma and an unruptured aneurysm of the right middle cerebral artery which probably the first report of these combinations in the English literature. Both lesions were treated surgically in one session with favorable outcome. Magnetic resonance angiography should be performed in patients with brain tumor preoperatively not only to visualize neoplastic vascularization but also to pick up incidental aneurysm.

http://bit.ly/2Tn7b5L

Jejunal diverticulitis

Abstract

Cases of small bowel diverticulitis, excluding Meckel's diverticulitis, are rare. Small bowel diverticular disease has been reported in approximately 0.3–1.3% cases of post mortem studies (Fisher JK, Fortin D. Partial small bowel obstruction secondary to ileal diverticulitis. Radiology 1977;122:321–322.) and in only 0.5–1.9% of contrast media study cases (Cattell RB, Mudge TJ. The surgical significance of duodenal diverticula. N Engl J Med 1952;246:317–324). Diverticula located within the small bowel may have presentations and complications similar to that of colonic diverticular disease. However, there is no consensus for the management for small bowel diverticulitis. Given that small bowel diverticulitis, like a colonic diverticulitis, can cause an acute abdomen, surgical intervention may be required. In this particular case, a patient presented with symptoms of lower abdominal pain, nausea and fever. Following an x-ray and CT scan, the patient underwent an open laparotomy and small bowel resection of a portion of jejunum that contained a symptomatic diverticulum.

http://bit.ly/2Bgq9nH

Myogenic fibrosis of the flexor tendons after amphetamine drug abuse

Abstract

Myogenic fibrosis of the flexor tendons in a 23-year-old patient was caused by intense drug abuse. He was presented in the clinic with spastic flexor tendon contracture of his right hand. The patient was treated by tendon elongation with a satisfactory result. The treatment of flexor tendon contracture in those cases is very difficult and needs to be done in a complex way.

http://bit.ly/2TjEGGd

Anterior mediastinal mass 4 years after type A aortic dissection

Abstract

A 47-year-old male who previously underwent emergency surgery for type A aortic dissection presented to the emergency department 4 years later with acute chest pain radiating to his back and a significant drop in hemoglobin. Clinical presentation was concerning for aortic graft failure, but imaging revealed a large (6.0 × 3.2 × 12.8 cm³) soft tissue mediastinal mass that was not present 4 years before. Pathologic analysis revealed a rare thymic cyst with a hemorrhagic component. This was a challenging case from diagnostic and operative perspectives, involving the expertise of both cardiac and thoracic surgical teams.

http://bit.ly/2BffM3t

A novel case of late left ventricular outflow tract obstruction post mitral valve surgery

Abstract

Left ventricular outflow tract (LVOT) obstruction (LVOTO) is a rare but recognized complication of mitral valve surgery. Concomitant factors can cause significant clinical deterioration which requires urgent intervention. We present the case of a female patient who underwent closed valvotomy at age 20 for mitral stenosis secondary to rheumatic heart disease. Seventeen years later, a re-stenosed valve prompted mitral valve replacement (MVR) with a Carbomedics mechanical prosthesis. 8 years later, she re-presented with increasing dyspnoea. On echocardiogram a frond-like structure was visible in the LVOT, the valve housing was protruding into the LVOT and she had marked septal hypertrophy. The LVOT gradient was 72 mmHg. This is a novel case of mechanical MVR associated LVOTO due to at least three discrete factors. This case demonstrates how multiple factors can amalgamate to result in significant clinical deterioration. Over an 8-year period, all three distinct factors contributed to the development of severe LVOTO.

http://bit.ly/2TjEAOR

Unusual Manifestation of Ulcerative Colitis

The relationship of inflammatory bowel disease (IBD) and chronic recurrent multifocal osteomyelitis (CRMO) is understood as extraintestinal rheumatic manifestations. CRMO is a chronic, relapsing, inflammatory, noninfectious disorder of the skeletal system of unknown origin. The disease course is not always recurrent. The association of CRMO and ulcerative colitis (UC) is very rarely reported. We report a case of a 10-year-old Saudi female who was diagnosed with CRMO, when she developed fever in association with left foot pain, and ulcerative colitis was confirmed endoscopically and histologically based on a previous settled diarrheal illness and severe iron deficiency anemia which required blood. Both conditions responded well to IBD therapy. To the best of our knowledge, this is the first reported case of chronic, multifocal osteomyelitis associated with pediatric UC in Saudi Arabia. This report supports the use of IBD therapy in treating CRMO.

http://bit.ly/2CXBMjg

Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report

Neuromyelitis optica spectrum disorders are severe autoimmune inflammatory diseases of the central nervous system associated with the presence of immunoglobulin G antibodies against the water channel protein a...

http://bit.ly/2COIEiU

Severe Influenza A(H1N1) Virus Infection Complicated by Myositis, Refractory Rhabdomyolysis, and Compartment Syndrome

Myositis is a rare and morbid complication of influenza infection that can rapidly progress to rhabdomyolysis with acute renal failure. Here, we describe a 35-year-old obese woman with severe influenza A(H1N1) virus infection complicated by myositis, refractory rhabdomyolysis, and compartment syndrome.

http://bit.ly/2DJN1xz

Withdrawn: Prenatal thoraco-amniotic chest drain insertion to manage a case of fetal hydrops secondary to FOXC2

http://bit.ly/2MCL7l4

Glucose control in the ICU

Purpose of review Critically ill patients usually develop hyperglycemia, which is associated with adverse outcome. Controversy exists whether the relationship is causal or not. This review summarizes recent evidence regarding glucose control in the ICU. Recent findings Despite promising effects of tight glucose control in pioneer randomized controlled trials, the benefit has not been confirmed in subsequent multicenter studies and one trial found potential harm. This discrepancy could be explained by methodological differences between the trials rather than by a different case mix. Strategies to improve the efficacy and safety of tight glucose control have been developed, including the use of computerized treatment algorithms. Summary The ideal blood glucose target remains unclear and may depend on the context. As compared with tolerating severe hyperglycemia, tight glucose control is well tolerated and effective in patients receiving early parenteral nutrition when provided with a protocol that includes frequent, accurate glucose measurements and avoids large glucose fluctuations. All patient subgroups potentially benefit, with the possible exception of patients with poorly controlled diabetes, who may need less aggressive glucose control. It remains unclear whether tight glucose control is beneficial or not in the absence of early parenteral nutrition. Correspondence to Greet Van den Berghe, MD, PhD, Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, B-3000, Leuven, Belgium. Tel: +32 16 344021; fax +32 16 344015; e-mail: greet.vandenberghe@kuleuven.be Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.

http://bit.ly/2DGGzHt

Thoracic trauma in military settings: a review of current practices and recommendations

Purpose of review To examine current literature on thoracic trauma related to military combat and to explore its relevance to the civilian population. Recent findings Damage control resuscitation (DCR) has improved the management of hemorrhaging trauma patients. Permissive hypotension below 110 mmHg and antifibrinolytic use during DCR is widely accepted, whereas the use of freeze-dried plasma and whole blood is gaining popularity. The Modified Physiologic Triaging Tool can be used for primary triage and it may have applications in civilian trauma systems. Although Tactical Combat Casualty Care protocol recommends the Cric-Key device for surgical cricothyroidotomies, other devices may offer comparable performance. Recommendations for regional anesthesia after blunt trauma are not well defined. Increasing amounts of evidence favor the use of extracorporeal membrane oxygenation for refractory hypoxemia and resuscitative endovascular balloon occlusion of the aorta (REBOA) for severe hemorrhage. REBOA outcomes are potentially improved by partial occlusion and small 7 Fr catheters. Summary The Global War on Terror has provided opportunities to better understand and treat thoracic trauma in military settings. Trauma registries and other data sources have contributed to significant advancements in the management of thoracic trauma in military and civilian populations. Correspondence to Robert Mansky, 545 First Ave, Apt 8I, New York, NY 10016, USA. Tel: +1 516 672 5589; e-mail: rmansky@gmail.com Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.

http://bit.ly/2UoSVJW

Noninvasive ventilation versus oxygen therapy in patients with acute respiratory failure

Purpose of review High-flow nasal cannula oxygen therapy (HFOT) is becoming an alternative to noninvasive ventilation (NIV) and standard oxygen in management of patients with acute respiratory failure. Recent findings Patients with de novo acute respiratory failure should be managed with HFOT rather than NIV. Indeed, the vast majority of patients with de novo respiratory failure meet the criteria for ARDS, and NIV does not seem protective, as patients generate overly high tidal volume that may worsen underlying lung injury. However, NIV remains the first-line oxygenation strategy in postoperative patients and those with acute hypercapnic respiratory failure when pH is equal to or below 7.35. During preoxygenation, NIV also seems to be more efficient than standard oxygen using valve-bag mask to prevent profound oxygen desaturation. In postoperative cardiothoracic patients, HFOT could be an alternative to NIV in the management of acute respiratory failure. Summary Recent recommendations for managing patients with acute respiratory failure have been established on the basis of studies comparing NIV with standard oxygen. Growing use of HFOT will lead to new studies comparing NIV versus HFOT in view of more precisely defining the appropriate indications for each treatment. Correspondence to Jean-Pierre Frat, Médecine Intensive Réanimation, CHU de Poitiers, 2 rue la Milétrie, 86021 Poitiers Cedex, France. Tel: +33 5 49 44 40 07; e-mail: jean-pierre.frat@chu-poitiers.fr Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.

http://bit.ly/2DJ5pa0

The effectiveness of noise interventions in the ICU

Purpose of review Excessive noise has direct adverse physiological and psychological effects, and may also have indirect negative health consequences by reducing sleep quality and quantity. This review presents a synthesis of the epidemiology of noise in the ICU, and the potential interventions designed to attenuate noise and protect patients. Recent findings Noise increases cortisol release, oxygen consumption, and vasoconstriction. ICU noise levels are excessive throughout the 24-h cycle, irrespective of level of intervention or whether the patient is in a side room or open ward. Direct measurement suggests that noise is a substantial contributor to poor sleep quantity and quality in the ICU and is frequently recalled by survivors of critical illness as a negative experience of ICU admission. Noise abatement, environmental masking and pharmacological interventions may all reduce the impact of noise on patients. However, the sustainability of behavioural interventions remains uncertain and high-quality evidence demonstrating the benefit of any intervention on patient-centered outcomes is lacking. Summary Noise levels in the ICU are consistently reported to reach levels likely to have both direct and indirect adverse health consequences for both patients and staff. Noise reduction, abating the transmission of noise and pharmacological modulation of the adverse neural effects of noise are all potentially beneficial strategies, although definitive evidence of improved patient-centered outcomes is lacking. Correspondence to Lori Delaney, MIHM, MN, PGD Crit Care, PGC Ed, Faculty of Nursing, Queensland University of Technology, Kelvin Grove, QLD 4059, Australia. E-mail: Lori.delaney@qut.edu.au Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.

http://bit.ly/2UpOJJV

Telemedicine in the ICU: clinical outcomes, economic aspects, and trainee education

Purpose of review The evidence base for telemedicine in the ICU (tele-ICU) is rapidly expanding. The last 2 years have seen important additions to our understanding of when, where, and how telemedicine in the ICU adds value. Recent findings Recent publications and a recent meta-analysis confirm that tele-ICU improves core clinical outcomes for ICU patients. Recent evidence further demonstrates that comprehensive tele-ICU programs have the potential to quickly recuperate their implementation and operational costs and significantly increase case volumes and direct contribution margins particularly if additional logistics and care standardization functions are embedded to optimize ICU bed utilization and reduce complications. Even though the adoption of tele-ICU is increasing and the vast majority of today's medical graduates will regularly use some form of telemedicine and/or tele-ICU, telemedicine modules have not consistently found their way into educational curricula yet. Tele-ICU can be used very effectively to standardize supervision of medical trainees in bedside procedures or point-of-care ultrasound exams, especially during off-hours. Lastly, tele-ICUs routinely generate rich operational data, as well as risk-adjusted acuity and outcome data across the spectrum of critically ill patients, which can be utilized to support important clinical research and quality improvement projects. Summary The value of tele-ICU to improve patient outcomes, optimize ICU bed utilization, increase financial performance and enhance educational opportunities for the next generation of providers has become more evident and differentiated in the last 2 years. Correspondence to Christian D. Becker, MD, PhD, Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA. Tel: +1 914 493 1040; fax: +1 914 493 8373; e-mail: christian.becker@wmchealth.org Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.

http://bit.ly/2DHWsxz

Intra-atrial course of the right coronary artery: depiction of a potentially hazardous entity on dual-source CT

http://bit.ly/2Upm8o7

Takotsubo cardiomyopathy triggered by status epilepticus: case report and literature review

Takotsubo cardiomyopathy (TC) is acute stress-induced cardiomyopathy with characteristic transient wall motion abnormalities. TC has a clinical presentation similar to an acute coronary syndrome, including chest pain or dyspnoea, ECG changes and elevated cardiac enzymes. TC often occurs after emotional stress. There are approximately 50 TC cases reported related to seizure activity, and our review revealed 15 articles which were associated with status epilepticus. This condition can be a serious complication of seizures. We report a case of TC after status epilepticus in a patient who had been seizure-free for 20 years.

http://bit.ly/2DI3TVy

Fusobacterium necrophorum sepsis after tonsillitis/pharyngitis

Fusobacterium necrophorum is a rare infection most notable for causing Lemierre's syndrome. This consists of a primary oropharyngeal infection and septic thrombophlebitis, and one or more metastatic focus. Prior to the widespread use of antibiotics, Lemierre's syndrome commonly followed a rapidly progressing course, with a high mortality. We describe a case of a previously well 18-month-old boy who presented to the emergency department with a 3-week history of progressive, right-sided, painful neck swelling and systemic sepsis. He was initially treated conservatively with intravenous antibiotics, but ultimately required surgical drainage. Lemierre's syndrome is a rare condition with increasing incidence which can have significant adverse outcomes including death. Early recognition and treatment are essential, but identifying Lemierre's disease is challenging.

http://bit.ly/2DJfFPp

Stroke or side effect? dofetilide associated facial paralysis after direct current cardioversion for atrial fibrillation

Dofetilide is a class III antiarrhythmic drug that has proven efficacious in maintaining sinus rhythm in up to 60% of patients with persistent atrial fibrillation. Dofetilide's most concerning adverse effect is QT prolongation and polymorphic VT, but providers should be aware of other rare significant side effects. We report a case of dofetilide associated Bell's palsy masquerading as stroke that developed shortly after a cardioversion. The patient's facial weakness, a side effect of dofetilide, resolved relatively quickly after discontinuation of the medication and a short course of oral corticosteroids.

http://bit.ly/2UsZSd3

Proximal tibiofibular joint dislocation: a rare entity

A 37-year-old woman was diagnosed with an isolated proximal tibiofibular joint dislocation (PTJD) after an accident during gymnastic exercise. The dislocation has a low incidence rate and is often missed in the emergency department as physical and radiology signs are subtle. Treatment consists of closed or open reduction and immobilisation. When it is not recognised it is associated with significant peroneal nerve injury.

http://bit.ly/2DIVcuc

Placental chorioangioma associated with polyhydramnios and hydrops fetalis

A 27-year-old multigravida woman was noted on routine growth scan at 27 weeks gestation to have a central placental hypoechoic area measuring 6.7x6.0x4.4 cm. A subsequent magnetic resonance scan confirmed a solid mass in the placenta lying anteriorly; therefore, a preliminary diagnosis of giant placental chorioangioma was made. A repeat ultrasound scan at 30 weeks gestation indicated that the mass had increased, with the presence of polyhydramnios. The patient experienced reduced fetal movements at 31 weeks gestation. There was persistent fetal tachycardia at 33 weeks gestation, and consequently the neonate was delivered by emergency caesarean section. The placenta revealed a large chorioangioma. The neonate's birth weight was 2.85 kg and non-immune hydrops fetalis was diagnosed. The neonate improved significantly in the neonatal intensive care unit and is currently well with no medical problems.

http://bit.ly/2Upm4ET

Erythema ab igne as a complication of cannabinoid hyperemesis syndrome

http://bit.ly/2DI1cmH

Bacteraemia and multiple liver abscesses due to Fusobacterium nucleatum in a patient with oropharyngeal malignancy

Fusobacterium infections can have a wide clinical spectrum, ranging from mild infections to severe sepsis and abscess formation. This range depends partly on the patient's underlying conditions, such as immunosuppression or malignancy. Fusobacteria are commensal rods in the oropharyngeal cavity and digestive tract, but should mucosal barrier disruption occur, in the presence of the above-mentioned predisposing conditions, fusobacteria can spread and cause infections in the soft tissues, liver and so on. An elderly woman was admitted with an altered level of consciousness (lethargy). The ensuing workup revealed a posterior oral cavity tumour (squamous cell carcinoma), Fusobacterium nucleatum bacteraemia and liver abscesses. Due to the severe sepsis, the patient was referred to our intensive care unit, but she passed away despite antibiotic treatment.

http://bit.ly/2Upm1sH

Alports syndrome and intracranial aneurysm: mere coincidence or undiscovered causal relationship

A 44-year-old Caucasian man with a history of deceased donor renal transplant for end-stage renal disease from Alport's syndrome (AS), presented with a spontaneous subarachnoid haemorrhage and hydrocephalus. Following an external ventricular drain for the hydrocephalus, a CT angiography revealed a dissection of the left vertebral artery extending into vertebro-basilar junction necessitating a bypass between left occipital artery to left posterior inferior cerebellar artery. He had a posterior fossa Craniectomy, C1 laminectomy and coiling off, of the left vertebral artery. Postprocedure course was prolonged but uneventful with complete recovery and normal renal function 18 months postpresentation. AS, a disease caused by abnormalities in the synthesis of type IV collagen, can cause aneurysms with severe and permanent neurological sequalae. We present a case of AS with intracranial arterial dissection with potential life-threatening consequences and discuss the genetic and molecular basis of AS along with review of the relevant literature.

http://bit.ly/2DI3Vg8

Disseminated intestinal basidiobolomycosis with mycotic aneurysm mimicking obstructing colon cancer

Basidiobolomycosis is a rare fungal infection that may affect the gastrointestinal tract. It is caused by Basidiobolus ranarum and less than 80 cases have been reported in the literature. The incidence seems to be higher in the Middle East and in particular Saudi Arabia where most cases are diagnosed in the south-western region. An 18-year-old woman presented to the emergency department with an obstructing caecal mass initially suspected to be malignant. Surgical resection was complicated by bowel perforation, histology and cultures confirmed basidiobolomycosis infection. The postoperative course was complicated by an enterocutaneous fistula, fungal intra-abdominal abscesses, liver and lung abscesses, formation of mycotic hepatic artery aneurysm and meningoencephalitis. The patient eventually expired due to sepsis despite aggressive treatment. Diagnosis and management of such rare cases are very challenging and require a multidisciplinary approach. Complications are common and associated with a high mortality.

http://bit.ly/2UplW8n

Emergency management of massive haemoptysis

In this manuscript, we present a rare case of massive haemoptysis secondary to rupture of a pulmonary artery aneurysm, which was unusual for having occurred in the absence of tuberculosis or a vasculitis. We describe the emergency management of this that ultimately resulted in the patient's survival from both an anaesthetic and surgical perspective, as well as discuss the role of interventional radiology in this situation.

http://bit.ly/2UwbJqV

Invasive aspergillosis complicating treatment with tyrosine kinase inhibitors

We describe three cases of pulmonary aspergillosis (PA) in three patients without traditional risk factors for invasive aspergillosis infection, such as prolonged neutropenia or high dose systemic corticosteroid therapy. All three patients developed PA while taking tyrosine kinase inhibitors (TKI) and sustained greater clinical improvement once TKI were withdrawn. Our case series supports the theory TKI treatment can increase susceptibility to PA without causing neutropenia. Recognition that TKI treatment may predispose to invasive aspergillosis will allow for rapid recognition of affected patients and more effective management of future cases.

http://bit.ly/2UplJlB

Tubulointerstitial nephritis and uveitis syndrome in a female adult

Tubulointerstitial nephritis and uveitis (TINU) syndrome is a rare disease characterised by the association of acutetubulointerstitial nephritis and uveitis. It affects mainly children and young women. Drugs and infections may be precipitating factors. It is a diagnosis of exclusion. The mainstays of treatment are topical and systemic corticosteroids. Prognosis is usually favourable. We report a case of TINU which occurred in our unit. A 37-year-old woman presented with an influenza-like illness, bilateral ocular pain and blurred vision. Ophthalmological evaluation revealed bilateral anterior uveitis and later renal involvement was seen as acute tubulointerstitial nephritis. A diagnosis of TINU was assumed after exclusion of other systemic diseases. She was treated with topical corticosteroids for the uveitis and evolved favourably, with resolution of ocular symptoms and normalisation of serum creatinine and proteinuria. This case highlights the importance of a high degree of clinical suspicion to make the diagnosis of TINU syndrome.

http://bit.ly/2DK2EVT

Acute ischaemic stroke-related choreoathetosis treated with arterial thrombectomy

A rare case of acute choreoathetosis after acute stroke is presented. This 66-years-old, right-handed Caucasian woman presented with weakness of her right arm and right leg with dysarthria, which resolved by the time she arrived in the emergency department. No obvious focal sign apart from the abnormal choreoathetoid movement of the right arm and leg and of the neck was present. Her medical history included atrial fibrillation without anticoagulation. CT head was nil acute (Alberta Stroke Program Early CT Score of 10). CT angiography of the carotids showed a hyperdense M2 segment of the left middle cerebral artery. Intravenous thrombolysis immediately followed by thrombectomy was decided. Using the Penumbra aspiration device (ACE 68) two clots were removed with two aspirations. A small distal clot remained but partial recanalisation (Thrombolysis in Myocardial Infarction/Thrombolysis in Cerebral Infarction 2b) was achieved. 30 seconds after restoring blood flow, the choreoathetoid movements ceased. The patient was brought to intensive care for further monitoring, which was uneventful.

http://bit.ly/2Um2CsG

Persistent sciatic artery resembles a soft-tissue sarcoma in presentation

Persistent sciatic artery (PSA) is a rare vascular anomaly with estimated incidence of 0.03%–0.06%. It has high incidence of complications including aneurysmal formation and ischaemia that may lead to amputation. During early embryonic development, the sciatic artery (which usually supply fetal lower buds and caudal part) disappears when the superficial femoral artery develops properly and the lower limbs grow. On clinical examination, usually a pulsating gluteal mass (the aneurysm) is appreciated with weak or absent femoral artery (Cowie's sign). However, our patient had presented in a different way. She was referred from peripheral clinic as a case of possible liposarcoma in the gluteal region. On examination, there was obvious asymmetry between both buttocks. The affected side was hard, firm in consistency with no appreciable pulsation. Nevertheless, on auscultation there was a bruit of low grade. Peripheral pulses were palpable. Our clinical impression was towards a sarcoma namely a liposarcoma. MRI was requested to evaluate the mass. The radiology report suggested that most probably it is an angiosarcoma with slim possibility of being a cavernous haemangioma. The trucut biopsy was deferred, in view of the high vascular nature of the lesion. The plan was as follow: To do angiography and embolisation of the main feeding vessels, with the possibility of biopsy in a second incident if indicated.During the conventional angiography, the pathology revealed itself. The patient was type 3 according to Pillet-Gauffre classification (PSA is limited to gluteal area and the popliteal artery arising from the femoral artery) associated with huge arteriovenous malformation. Embolisation with different materials including coils, beads and foam was ineffective. Finally, the radiologist excluded the root of the sciatic artery by a stent bridging from common iliac to external iliac artery. This successfully occluded the PSA.

http://bit.ly/2DIn55e

Congenital lateral cleft palate with unilateral craniofacial microsomia and lateral ankyloglossia

Craniofacial microsomia is a group of anomalies that occur due to developmental defects in the first and second branchial arches during the embryological period. The disease has various craniofacial and extracraniofacial presentation patterns. Lateral cleft palate is distinct from the most common palate clefts because it is located lateral to the uvula. The presence of a lateral cleft palate has been very rarely reported in the literature, and the aetiopathogenesis of the disease is still not well understood. We aimed to report a case of the coexistence of lateral cleft palate and craniofacial microsomia and discuss the aetiopathogenesis of these diseases.

http://bit.ly/2Un2mte

Headache and inflammatory bowel disease: think cerebral vein!

Cerebral vein thrombosis is a severe complication of inflammatory bowel disease, can cause non-specific symptoms and hence lead to delay in diagnosis. We report the case of an adolescent with inflammatory bowel disease who developed extensive cerebral vein thrombosis requiring a ventriculoperitoneal shunt. Diagnosis was markedly delayed due to repeated misinterpretation of clinical signs and laboratory findings and the lack of reconsidering the working diagnosis despite the involvement of several medical subspecialties. The patient does not suffer from any neurological impairment. This case report highlights the need for clinicians to maintain vigilance for complications of chronic disease and encourages to cast doubt on the working diagnosis constantly.

http://bit.ly/2DI3Tow

Rivaroxaban-related acute kidney injury in a patient with IgA vasculitis

Anticoagulants have recently been recognised as a cause of acute kidney injury (AKI). We describe the case of a 75-year-old man with IgA vasculitis and atrial fibrillation treated with rivaroxaban, who presented with macroscopic haematuria and an acute decline in renal function. Two months before referral, he noted palpable purpuric lesions and was diagnosed with IgA vasculitis based on skin biopsy findings; the skin lesion disappeared following treatment with a steroid external preparation. Renal biopsy revealed glomerular haemorrhage and red blood cell casts. Although rivaroxaban was withdrawn, his kidney function worsened and he was started on haemodialysis. His renal function did not recover. To the best of our knowledge, this is the first case of direct oral anticoagulant (DOAC)-related AKI in systemic vasculitis. During DOAC therapy, close monitoring of a patient's urinalysis results and their renal function may be required for patients with systemic vasculitis to avoid AKI.

http://bit.ly/2DImUqA

Synovial sarcoma in an HIV-positive pregnant woman and review of literature

We present a first case of synovial sarcoma in an HIV-positive pregnant woman. This 28-year-old woman was diagnosed with synovial sarcoma, a high-grade malignant soft tissue sarcoma, involving her left thigh during the first trimester of her pregnancy. She underwent surgical treatment in the form of hip disarticulation at 30 weeks' gestation. She was subsequently delivered by emergency caesarean section (CS) at 34 weeks' gestation when she presented with wound sepsis and a scan revealed static growth in a small for gestational age fetus. Prompt diagnosis and treatment of this aggressive tumour is important and should involve a multidisciplinary approach, with a balanced consideration of the maternal and fetal outcomes.

http://bit.ly/2UrKCgi

Gross anterior segment ischaemia following vitreoretinal surgery for sickle-cell retinopathy

We report the case of a 32-year-old Afrocaribbean man with known stage 3 proliferative sickle-cell retinopathy who presented with a mixed picture of tractional and rhegmatogenous macula off detachment. He underwent left primary 25 g vitrectomy with silicone oil, delamination and endolaser photocoagulation under a general anaesthetic. He, however, presented 48 hours postoperatively with gross anterior segment ischaemia. His pain and ocular signs settled over the course of a few days following administration of supplemental oxygen, oral steroids, analgesia and intravenous hydration. Examination showed resolution of his proptosis and orbital signs as well as anterior segment inflammation. He remains under follow-up.

http://bit.ly/2DImO2c

Treatment of Ethylene Glycol Poisoning with Oral Ethyl Alcohol

Ethylene glycol poisoning is not uncommon in India. The ill effects are primarily caused by its toxic metabolites: glycolic acid and oxalic acid. A 70-year-old female presented to our hospital with ataxia after ingestion of ethylene glycol. The reported case describes the management of ethylene glycol poisoning using oral ethyl alcohol as an alternative to the recommended intravenous ethyl alcohol and fomepizole that are not available for use in India. The need for high degree of clinical suspicion, targeted investigations, and early instigation of treatment is of prime importance in cases of ethylene glycol poisoning as it can lead to long-term complications or even death.

http://bit.ly/2B9Jbfs

Trousseau syndrome in a patient with advanced oral squamous cell carcinoma: a case report

Trousseau syndrome is known as a variant of cancer-associated thrombosis. Trousseau syndrome commonly occurs in patients with lung or prostate cancer. Hypercoagulability is thought to be initiated by mucins pr...

http://bit.ly/2UpuMCS

EBV Infection Unmasking a Choledochal Cyst in an Infant

Hepatic involvement is common in acute Epstein–Barr virus (EBV) infection in children. It usually manifests as a transitory elevation of transaminases in up to 80% to 90% of patients, and they normalize by 2 to 6 weeks. A cholestatic pattern with elevated gamma-glutamyl transferase (γGT) and alkaline phosphatase (ALP) is common, in up to 60% in young adults. However, jaundice is very rare occurring in only 5% of pediatric patients. We report here an 8-month-old female with EBV infection who developed obstructive jaundice 2 weeks after the initial infection. Radiologic investigations were compatible with choledochal cyst type IVa complicated by stone formation in the common bile duct. In case of clinical exacerbation or nonamelioration of liver function tests in EVB infection, another diagnosis should be addressed. This highlights the importance of close follow-up in these patients in order not to miss a serious underlying condition such as choledochal malformation.

http://bit.ly/2sP0M7S

Acute blue finger syndrome: a rare benign cause of acute digit discolouration

Acute blue finger syndrome is a rare benign condition that mimics digital ischaemia. We discuss the case of a 32-year-old woman who presented with a 6hour history of blue discolouration of the middle finger of the right hand, associated with pain and swelling. There was no history of trauma and this was the first time that the patient had experienced these symptoms. Examination found blue discolouration of the digit primarily on the volar aspect with associated swelling. All investigations, including blood tests, X-rays and Doppler scanning, were normal. The symptoms resolved spontaneously within 48 hours. There were no recurrent episodes or long-term sequelae. Patients presenting with an acutely blue finger need rapid assessment to exclude digit ischaemia. Knowledge of this rare benign condition may prevent unnecessary distress, invasive investigations and potentially harmful treatment of a healthy patient.

http://bit.ly/2CS80N6

Examination under anaesthesia of the rectum for removal of gallstones

http://bit.ly/2RXWGcH

Rare case with plethora of upper urinary tract anomalies associated with pelviureteric junction obstruction: a surgical challenge managed with robot assistance

The genitourinary system for reasons unknown is more likely to have birth defects than any other system. The anomaly of collecting system draining the kidney represent mystifying subset of congenital anomalies. Pelviureteric junction obstruction (PUJO) is most common. Chronic obstruction can lead to stasis, urinary infection and stone formation in PUJO. Extrarenal calyces, which is characterised by presence of calyces and renal pelvis outside the renal parenchyma is one of the rare anomalies seen among the collecting system right gonadal vein drains into inferior vena cava. Its altered drainage into right renal vein is rarely seen and reported. Glut of these multiple anomalies in a single case is an extremely rare event. We hereby discuss a case of 40-year-old male patient with combination of all these anomalies and discuss the embryology, presentation and management.

http://bit.ly/2CTrJMt

Primary Ewing sarcoma of the kidney

Primary Ewing sarcoma (ES) or primitive neuroectodermal tumour (PNET) is a rare tumour in adults and primary renal involvement is extremely rare. Patients with renal ES or PNET respond to and would benefit from conventional ES treatment according to ES study protocols. Here, we report a case of a young woman, presenting with right flank pain and haematuria. After ultrasound and CT evaluation, a right middle pole renal mass was detected. The patient underwent radical right nephrectomy, and a grade 4 ES with peritoneal involvement was documented. Subsequently, the patient underwent adjuvant chemotherapy for 5 months. Follow-up 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scan demonstrated bilateral cervical, hilar, mediastinal and retroperitoneal FDG-avid adenopathies associated with mild right-sided pleural effusion with no metabolic activity, signifying the role of PET/CT scan in tumour restaging.

http://bit.ly/2RU0Lyh

Ileal conduit volvulus: rare complication of urinary diversion

Ileal conduit volvulus is a rare complication of urinary diversion. It has been suggested that various factors including prolonged length of the ileal segment, lack of fixation of the conduit to the peritoneum and failure to close the incised mesentery predispose patients to this complication. We present the case of a 76-year-old man who presented to hospital with severe abdominal pain and oliguria secondary to a volvulus of his ileal conduit. Investigations revealed early acute kidney injury as a result of urinary obstruction which was evident on abdominal CT. The patient subsequently underwent operative repair of the volvulus. Symptoms resolved following the procedure, kidney function improved and the patient was discharged without complication.

http://bit.ly/2CRvLVj

Incidental detection of asymptomatic pneumothorax resulting in a diagnosis of Birt-Hogg-Dube syndrome

http://bit.ly/2RXWydd

Peroneal artery entrapment syndrome (PRAES): a rare cause of ischaemic toes

A 75-year-old man presenting with intermittent discolouration of his left toes was referred to vascular surgery with suspicion of embolic vascular disease. A contrast-enhanced MR angiogram was performed which revealed bilateral dominant peroneal arteries (PRAs). There was evidence of short atherosclerotic stenosis directly at the point where the left PRA passes through the tibiofibular interosseous membrane which we postulate to be the source of the emboli. We present what is believed to be the first reported case of PRA entrapment complicated by distal toe emboli.

http://bit.ly/2CQlMQc

Behavioural changes as the first manifestation of a silent frontal lobe stroke

A 67-year-old man was admitted to our hospital after his relatives found him to have severe personality and behavioural changes. His behaviour was inappropriate and uninhibited. The patient reported no symptoms and he showed poor insight into his own behaviour. Neuroimaging showed an orbitofrontal lesion, due to an infarction of the anterior cerebral artery. The patient was diagnosed with frontal lobe syndrome.

http://bit.ly/2RXWvy3

Double axillary vein variation diagnosed with ultrasound guidance during infraclavicular nerve block intervention

The use of ultrasound guidance increases the safety of peripheral block interventions by allowing anaesthesiologists to simultaneously see the position of block needle, the targeted nerves and surrounding vessels. In this report, we represented three patients diagnosed with double axillary vein variation with ultrasound guidance during infraclavicular nerve block intervention. The patients were scheduled for different types of upper limb surgeries. All patients received infraclavicular nerve block for anaesthetic management. A double axillary vein variation was diagnosed with ultrasound during block interventions. Hydro-location technique was used in all cases and the procedures were completed uneventfully. In the current literature, there is limited number of reports concerning double axillary vein variation. Detailed knowledge of the axillary anatomy is important to avoid complications such as intravascular injection during peripheral nerve block interventions. The use of ultrasound guidance and hydro-location technique should be considered for nerve blocks, especially in the axillary area.

http://bit.ly/2CPtA4D

Pseudomonas meningoencephalitis masquerading as a stroke in a patient on tocilizumab

A previously high-functioning woman presents with clinical and CT features of a subacute ischaemic stroke. Her medical history is relevant for refractory giant cell arteritis on long-term high-dose prednisolone and recent commencement of tocilizumab (interleukin-6 monoclonal antibody). The potential for stroke mimic is considered and a magnetic resonance brain scan is requested. She rapidly deteriorates within 24 hours of admission and unexpectantly dies. An autopsy reveals that she has bilateral pulmonary emboli with lower limb deep vein thrombosis and Pseudomonas meningoencephalitis with frank pus on the brain. We discuss the potential risks of immunosuppression and the role of imaging in the diagnosis of stroke.

http://bit.ly/2RRIeCZ

Intestinal obstruction caused by small bowel adenocarcinoma misdiagnosed as psychogenic disorder

We describe a case of intestinal obstruction caused by a small bowel adenocarcinoma misdiagnosed as psychogenic disorder. A woman in her 40s was admitted to Nagoya City University Hospital with fatigue, anorexia, nausea and vomiting. CT, oesophagogastroduodenoscopy and colonoscopy revealed no signs of organic abnormality in her gastrointestinal tract. As the patient had previously been diagnosed with and treated for depression, her symptoms were suspected to be due to psychogenic disorder. Therefore, she was diagnosed with severe depression and was administered antidepressant agents. Despite intense psychiatric treatment, her symptoms worsened and she was later diagnosed with ileus due to adenocarcinoma in the jejunum. After drainage by insertion of a transnasal decompression tube, a partial jejunum resection was performed. After the resection, the patient's symptoms including fatigue and depression resolved without the use of antidepressant agents.

http://bit.ly/2CPLoNi

Simultaneous presentation of thyroid storm and diabetic ketoacidosis in a previously healthy 21-year-old man

A 21-year-old young man with no history of diabetes or thyroid disease presented to the emergency department with simultaneous thyroid storm and diabetic ketoacidosis. Notable findings on admission were a ventricular rate of 235 beats/min, tachypnoea, tremors, polydipsia and a lack of fever. Due to the unusual constellation of symptoms, diagnosis was only possible after initial laboratory results came back. While the lack of fever is unusual in thyroid storm, diabetic ketoacidosis has previously been reported to suppress fever, and this case supports the occurrence of this phenomenon. This case was highly unusual because the patient had not previously been diagnosed with either type 1 diabetes or Graves' disease.

http://bit.ly/2RRMm5M

Rectal bleeding caused by a syphilitic inflammatory mass

A 47-year-old man presented with fatigue, decrease appetite, abdominal pain and rectal bleeding. His colonoscopy revealed a single, firm, raised, centrally ulcerated mass at the anorectal junction. During this same admission, he was diagnosed with HIV and syphilis, found to have multiple hepatic lesions and positive cerebrospinal fluidvenereal disease research laboratory test (VDRL). Biopsies from both the hepatic lesions and rectal ulcer showed spirochaetes by immunostaining. The initial presentation was felt to be secondary to a rectal inflammatory mass caused by syphilis.

http://bit.ly/2CP5qHJ

Hypocalcaemia and hyponatraemia masquerading the diagnosis of Gitelman syndrome

Gitelman syndrome is the most common renal tubulopathy, recently exhibiting a dramatic rise of incidence in Asia.

A 50-year-old woman presented with vomiting, fatigue and quadriparesis. Physical examination revealed a positive Trousseau sign , hypotonia and areflexia.

Suspecting hypocalcaemia, she was given intravenous 10% calcium gluconate (10 mL administered slowly over 10 min) but her manifestations persisted. An exhaustive laboratory work up revealed the diagnosis of Gitelman syndrome.

The peculiarity of this case however, is entailed in its coexistence with hypocalcaemia and hyponatraemia. In addition, the age of primary presentation being 50 years further culminates its atypicality.

Multiple electrolyte imbalances were corrected by oral and intravenous supplementation and a high sodium-potassium diet was advocated. Administration of spironolactone imposed a pitfall in the management of our patient due to exacerbation of pre-existing hyponatraemia.

On follow-up, her electrolyte profile was stable and corresponding symptoms were alleviated.

http://bit.ly/2RSmzdG

Aortitis and pachymeningitis: an unusual combination in granulomatosis with polyangiitis (myeloperoxidase-associated vasculitis)

Aortitis and pachymeningitis are uncommon manifestations of the antineutrophil cytoplasmic antibody-associated vasculitides, a group of systemic autoimmune diseases mainly affecting small vessels. We present a case of a 71-year-old woman with a remote history of idiopathic chronic granulomatous pachymeningitis complicated with aortic thickening due to autoimmune aortitis.

http://bit.ly/2CTQR5u

Hepatitis in patients with syphilis: an overlooked association

We present the case of a patient who sought treatment for fever and a maculopapular rash involving the trunk, limbs, palms and soles. The patient also presented with hepatomegaly and elevated levels of liver enzymes (with a higher increase of alkaline phosphatase). With the proposal of early syphilitic hepatitis, during the stage of secondary syphilis, a venereal disease research laboratory and Treponema pallidum haemagglutination tests were requested, which confirmed the diagnosis. All altered parameters improved with antibiotic treatment for secondary syphilis. Syphilitic hepatitis is an often overlooked presentation of syphilis and should be considered as a differential diagnosis in patients with elevated levels of liver enzymes and risk factors for syphilis.

http://bit.ly/2RXztXW

Actinomycosis of the omentum with invasion of the abdominal wall, small bowel and transverse colon mimicking malignancy

We report the case of a 59-year-old Russian man who presented with a painless, slow-growing, epigastric mass. CT revealed a large heterogeneous mass within the omentum infiltrating into adjacent tissues. During diagnostic laparoscopy, the omental mass was noted to be firm, raising the suspicion of malignancy. Surgical en-bloc resection of the mass, including the posterior rectus sheath, transverse colon and small bowel, was performed with primary anastomoses at laparotomy. Histological examination was inconsistent with malignancy and revealed the mass to be actinomycosis, confirmed by microscopy and gram staining. Surgical resection was followed by an 8-week course of penicillin and doxycycline antibiotic therapy. This treatment resulted in full clinical and radiological recovery with no complications. Although the clinical and radiological findings, in this case, were highly suspicious of malignancy, abdominal actinomycosis should be considered a differential diagnosis in patients with infiltrative abdominal masses and mild constitutional symptoms.

http://bit.ly/2CM1jfe

Largest giant juvenile fibroadenoma of the breast

Juvenile giant fibroadenoma is a rare benign tumour of the breast accounting for 0.5% of all fibroadenomas. The presentation can be very dramatic and may result in breast deformity and may mimic a rare malignant tumour. It is indeed a great challenge to provide the best treatment for these patients in terms of clinical and psychological care. Meticulous surgical planning is required to ensure a fine balance between adequate resection and the best cosmetic outcome for a developing breast. Every effort should be made to preserve the developing breast irrespective of the size of the tumour as it is in this case. We report the world's largest juvenile fibroadenoma of the breast in a 16-year-old girl who presented to our hospital with a 28x25 cm mass on her left breast in which breast conservation was done. A detailed literature search and management of these lesions are discussed.

http://bit.ly/2RXW86D

Very rare case of synchronous volvulus of the sigmoid colon and caecum causing large-bowel obstruction

Large-bowel obstruction caused by volvulus is potentially life threatening if not managed promptly. Sigmoid colon is the most common site of volvulus followed by caecum. Synchronous double colonic volvulus is an exceedingly rare entity, with only five cases published previously. We present the case of a 77-year-old man with a synchronous sigmoid and caecal volvulus. He underwent total colectomy with ileostomy formation with a view to reverse the ileostomy at a later date.

http://bit.ly/2CQrzFt

Nodular scleritis with strongly positive serum rheumatoid factor: forme fruste rheumatoid arthritis sans arthritis

http://bit.ly/2RTSRoM

A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: a case report

Immune thrombocytopenia is an acquired autoimmune disease. Recently, there has been evidence of thrombotic risk in patients with immune thrombocytopenia, but the mechanism is still inconclusive. Intravenous im...

http://bit.ly/2RkMKoq

Euglycemic Ketoacidosis in Spinal Muscular Atrophy

Euglycemic ketoacidosis is defined by the triad of high anion gap acidosis, increased plasma ketones, and the absence of hyperglycemia. Apart from diabetes mellitus, the disorder may occur in prolonged fasting, excessive alcohol consumption, pregnancy, and inborn errors of metabolism. Here, we highlight the diagnosis of euglycemic ketoacidosis in a pediatric nondiabetic patient with spinal muscular atrophy (SMA) type 1 (Werdnig–Hoffmann disease), who, subsequently to her postoperative admission to the intensive care unit following a spinal surgery, developed high anion gap metabolic acidosis. We discuss the pathophysiology of acid-base disorders in SMA, along with the glucose and fatty acids metabolism, the necessary knowledge for medical practitioners.

http://bit.ly/2RSzkVT

Undifferentiated epithelioid sarcoma presenting as a fever of unknown origin: a case report

Fever of unknown origin is often a diagnostic dilemma for clinicians due to its extremely broad differential. One of the rarer categories of disease causing fever of unknown origin is malignancies; of these, s...

http://bit.ly/2MAXWfY

“Crack, Reduce, and Implant”: A Safe Phaco Technique in a Case with Hard Brown Cataract

This report describes two maneuvers in different steps of phaco surgery in a case with hard cataract, which provide debulking of the central dense nucleus and prevents posterior capsule rupture (PCR). In the current case, clear corneal incisions were created, and anterior chamber was filled with ophthalmic viscosurgical device (OVD). Anterior capsule was punctured, and capsulorhexis was completed. Nucleus was cracked into two halves following vertical groove formation. Core nucleus was hollowed sideward bilaterally in the capsular bag. Nuclear halves were removed from capsular bag, and each one was pushed to one side on the iris plane. Capsular bag was inflated with OVD, and intraocular lens (IOL) was implanted. Nuclear halves were removed in confidence. The presented maneuvers initially reduce dense nucleus load in the safe zone and allow surgeon to use IOL as a barrier to protect floppy posterior capsule from early steps of the surgery.

http://bit.ly/2sMQJQH

Using the new INTRABEAM mobile intraoperative radiotherapy system during surgery for pancreatic cancer: a case report

Pancreatic cancer is one of the most common fatal malignancies and has a poor prognosis. Surgical treatment is the most important treatment method, but there is a low rate of radical excision; moreover, the po...

http://bit.ly/2CMw2cl

Clinical Trials News

Mon Jan 07, 2019 00:00

Clinical Trials Survey

Would you like to help improve the clinical research experience for patients? We are interested in your opinion about reporting your symptoms for clinical trials. Please click the link below to complete this short, 5-minute survey. Your anonymous responses will be used for research purposes to better understand how to improve patient care. Complete the survey and provide your email address to be entered to win a $100 Visa gift card! Thank you for taking the time to provide your opinion.

ClinicalConnection.com New Clinical Trials

Mon Jan 07, 2019 00:00

Schizophrenia - Princeton NJ

Do you or a loved one suffer from Schizophrenia? If so, Princeton Medical Institute located in Princeton, NJ is conducting a clinical research trial of an investigational treatment for Schizophrenia. We're seeking volunteers 18 to 65 years old who have been diagnosed with Schizophrenia Study-related exams, procedures, and medication are provided at no cost. Visit our website to learn more and submit your interest! Common Symptoms of Schizophrenia May Include: Withdrawal from reality Hallucinations...

ClinicalConnection.com New Clinical Trials

Sun Jan 06, 2019 00:00

Pediatric Plaque Psoriasis - Clearwater FL

Click image to enlargeLocal dermatologists are conducting a clinical research study to test the effectiveness and safety of an investigational topical medication for Plaque Psoriasis.Qualified Participants Must:Be 12-16 years old Provide consent and be accompanied by a legal guardian at the time of consent signing Have an Investigator's Global Assessment (IGA) score of at least 3 Be willing to comply with all study instructions and commit to follow-up visits Females must not be pregnant and agree...

ClinicalConnection.com New Clinical Trials

Fri Jan 04, 2019 00:00

<b>Eczema (Atopic Dermatitis) - Webster TX</b>

Click image to enlarge

ClinicalConnection.com New Clinical Trials

Thu Jan 03, 2019 00:00

<b>ADHD with Impulsive Aggression - Grand Prairie TX</b>

 Aggression refers to a behavior that can result in both physical and psychological harm to oneself, others or objects in the environment. Aggression is manifested verbally, mentally, and physically. Such behavior becomes maladaptive when it persists, occurs outside an acceptable social context, and is of an intensity, frequency, severity and/or duration detrimental to the child's interests. This is a double-blind, randomized, parallel group, two-arm, placebo-controlled study with flexible dosing...

ClinicalConnection.com New Clinical Trials

Thu Jan 03, 2019 00:00

Osteoarthritis of the Knee - La Mesa CA

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Woodstock GA

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Excessive Underarm Sweating Study for Children - Raleigh NC

Does Your Child Struggle with Excessive Underarm Sweat?Consider Joining a Clinical Research Study of a New MedicationWake Research is enrolling participants in a study of an investigational medication for excessive underarm sweat in children and teens.

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Phoenix AZ

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Remove ads

Osteoarthritis of the Knee - Albuquerque NM

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Kansas City MO

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Carmichael CA

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Edgewater FL

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - San Angelo TX

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Charleston SC

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

<b>Osteoarthritis of the Knee - Multiple Locations in the US</b>

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee - Cincinnati OH

Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Alzheimer's Disease - Spring Hill FL

If you are caring for someone with Alzheimer's disease, please consider the ROAD clinical research study, which will determine the safety and effectiveness of the multifunctional small moleculeAD-35 in patients with mild to moderate Alzheimer's disease (AD).Key Eligibility Criteria• Between 50 and 85 years of age (inclusive)• Diagnosed with probable AD in accordance with the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria• Mini-Mental State Examination (MMSE) score of ≥>...

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Child ADHD - Lakeland FL

Is your child is experiencing the following symptoms:  trouble staying focused, interrupts others, hyper or impulsive or does not listen, OR has already been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD)? If yes, learn more about a medical research study evaluating an investigational study drug in children 6 to 17 years of age. 

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two presentations highlighting the potential of Advaxis vectors to generate T cell responses to a large percentage of neoantigens and to promote antigen spreading and potentially slow progression of prostate cancer, were presented at the 2019 Keystone Symposia on Cancer Vaccines, held January 19-24

Business Wire Health: Clinical Trials News

Fri Jan 25, 2019 15:05

Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Strong Pipeline to Boost Growth | Technavio

LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Inhibitors?src=hash" target="_blank"gt;#Inhibitorslt;/agt;--The global PD-1 and PD-L1 Inhibitors market is expected to post a CAGR of over 19% during the period 2019-2023, according to Technavio.

Business Wire Health: Clinical Trials News

Fri Jan 25, 2019 14:00

Circassia to buy US, China marketing rights to AIT's AirNOvent

The acquired rights will cover all potential indications in the hospital setting for the administration of inhaled AirNOvent at up to 80 parts per million. One of the The post Circassia to buy US, China marketing rights to AIT's AirNOvent appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression

NV-5138 is a first-in-class, orally-active small molecule that directly activates mTORC1, the gatekeeper of cellular metabolism and renewal, which is suppressed in the brain of people suffering from The post Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

FDA accepts X-Rx's IND application for X-165 to treat IPF

X-165 is a highly potent and selective small molecule inhibitor of Autotaxin owned by X-Rx. An initial advanced lead series that led to the identification of X-165 was The post FDA accepts X-Rx's IND application for X-165 to treat IPF appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 08:54

EC approves Clovis' Rubraca to treat women with relapsed ovarian cancer

The second indication of Rubraca has been approved as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer The post EC approves Clovis' Rubraca to treat women with relapsed ovarian cancer appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Fri Jan 25, 2019 06:56

ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 8, 2019 to discuss its 2018 operating results. Management will also provide a brief update on the business. Conference Call InformationTo access the live call by phone, dial 323-794-2093; the conference ID is 6271602. The call may also be a

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 23:30

Immunomic to Present at the 2019 BIO CEO & Investor Conference

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its' founder and CEO, William Hearl, Ph.D., will present an overview of the company and its UNITE technology platform at the 2019 BIO CEO & Investor Conference on February 12, 2019 at 2:00 pm EST in the Hudson/Empire Room at the Marriott Marquis in New York City. About UNITE ITI's investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Assoc

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 23:05

Vermont Collaborative Partners with Netsmart to Alter Trajectory of Care for State's Most Vulnerable

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Four member agencies of Vermont Care Partners (VCP) have come together to reshape the delivery and coordination of care through a partnership with Netsmart to deploy a unified technology platform. As value-based care quickly becomes reality, Lamoille County Mental Health Services, Northwestern Counseling and Support Services, United Counseling Services of Bennington and Washington County Mental Health Services will leverage the full suite of solutions from

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 22:00

Remove ads

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Survival from BNS diagnosis (BNS survival), survival from ibrutinib initiation to last follow-up or death (ibrutinib survival), and time from ibrutinib initiation to ibrutinib discontinuation...

Blood CLINICAL TRIALS AND OBSERVATIONS

Thu Jan 24, 2019 19:00

Oyster Point Pharma to Present at the BIO CEO & Investor Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma to present a corporate overview at the BIO CEO & Investor Conference.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 17:33

Midwest Vision Research Foundation at Pepose Vision Institute Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts

ST. LOUIS, Mo.--(BUSINESS WIRE)--Midwest Vision Research Foundation at Pepose Vision Institute joins the AcuFocus IC-8® Lens clinical study for cataracts.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 16:05

Tamr Joins Accenture's Life Sciences Ecosystem to Help Drive Innovation in Drug Discovery and Scientific Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tamr Inc. today announced it has joined Accenture's open partner ecosystem, designed to help independent software vendors (ISVs) and life science companies team more effectively to accelerate drug discovery efforts and improve patient outcomes. The ecosystem is an integral part of Accenture's cloud-based informatics research platform, which has been designed to help life sciences organizations improve productivity, efficiency, and innovation in drug discovery.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 16:00

Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting

BOSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell announces data from NAM-NK and NiCord® programs to be presented at 2019 TCT Annual Meeting

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 15:32

X-Rx Announces FDA Acceptance of IND Application for X-165

WALTHAM, Mass.--(BUSINESS WIRE)--X-Rx Announces FDA Acceptance of IND Application for X-165

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 15:15

Can-Fite BioPharma CEO Letter to Shareholders

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that Pnina Fishman, Chief Executive Officer of Can-Fite Biopharma, has issued a Letter to Shareholders, the full text of which follows below. Dear Can-Fite Shareholders, It has been a very busy and productive year at Can Fite BioPharma, filled with c

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:30

Dicerna Evolves Its Board of Directors to Support Continued Growth

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna announced several changes to its board of directors, reflecting the company's ongoing growth.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:30

Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer

BURLINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ARQL&src=ctag" target="_blank"gt;$ARQLlt;/agt; lt;a href="https://twitter.com/hashtag/arql?src=hash" target="_blank"gt;#arqllt;/agt;--ArQule, Inc.'s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche's PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®),...

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;--Concert began a Phase 1 single-ascending dose trial to evaluate the safety, tolerability, and PK profile of CTP 692 in healthy volunteers.

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition filed by Capital Royalty Partners II, L.P. and affiliated entities. On August 27, 2018, Capital Royalty Partners II, L.P. and several affiliated entities ("CRG") filed a Petition with the Ohio Supreme Court seeking a

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00

Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt;--Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 13:59

BridgeBio Pharma raises $299.2m in financing round

BridgeBio Pharma will also use the funds to expand its efforts on the development of medicines for patients with unmet needs. Both existing investors KKR and Viking Global The post BridgeBio Pharma raises $299.2m in financing round appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 13:17

Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463

Data from the Phase 1 study are expected in the second half of 2019. "The initiation of this Phase 1 study with IW-6463 marks an important milestone for The post Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463 appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 11:20

BioNTech to acquire MAB Discovery's antibody generation unit

Under the terms of the agreement, BioNTech will acquire all assets, employees and proprietary know-how for mAb generation from MAB Discovery. MAB Discovery will retain ownership of and The post BioNTech to acquire MAB Discovery's antibody generation unit appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Thu Jan 24, 2019 13:17

ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorisation (CMA) Application for ANCA-Associated Vasculitis in Europe, Phase III Advocate Trial Data Release Planned for Q4 2019

ZURICH & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Regulatory News: ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd., a company of Vifor Pharma Group, today announced that in light of the upcoming availability of data from the pivotal Phase III ADVOCATE trial – the largest controlled trial in active anti-neutrophil cytoplasmic antibody associated vasculitis (ANCA-associated vasculitis) – they have decided to withdraw the application for Conditional Marketing Authorisation (CM

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 08:00

Gossamer Bio Announces Commencement of Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") in connection with the commencement of a proposed initial public offering of its common stock. Gossamer Bio is offering 14,375,000 sha

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 00:24

Advaxis' Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced receipt of notification from the U.S. Food and Drug Administration (FDA) that the Company's ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV) has been placed on partial clinical

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 23:05

Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders. Data from the Phase 1 study are expected in the second half of 2019. "The initiation of this Phase 1 study with IW-6463 marks an im

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 23:01

Vedanta Biosciences Announces Publication in Nature of Seminal Research Revealing A New Mechanism of Human Microbiota-Driven Antitumor Immunity Involving Induction of IFNy+ CD8+ T Cell Accumulation in the Gut and Tumors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences announced a publication in Nature that revealed a newly discovered mechanism underlying antitumor immunity.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 20:07

Remove ads

Modulated Imaging Raises $7M in Series B Funding

IRVINE, Calif.--(BUSINESS WIRE)--Modulated Imaging has raised $7 million in Series B funding to fund the commercialization of its Clarifi technology and clinical studies.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 19:30

Vascular Dynamics Names Prof. Martin Rothman Chief Medical Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--World-renowned interventional cardiologist Martin Rothman has been named chief medical officer at VDI.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 19:05

Redx gets regulatory nod to restart RXC004 clinical trial

An oral porcupine inhibitor, RXC004 has been designed to target the Wnt signaling pathway. The early-stage trial of the small molecule drug was temporarily stopped in March 2018 The post Redx gets regulatory nod to restart RXC004 clinical trial appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 17:43

U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology

VIENNA, Va.--(BUSINESS WIRE)--U.S. patent office issues CEL-SCI two patents for its LEAPS vaccine platform technology.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 16:20

Medidata Joins the World Economic Forum

NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MDSO?src=hash" target="_blank"gt;#MDSOlt;/agt;--Medidata (NASDAQ:MDSO) today announced that it has entered into a three-year strategic collaboration with the World Economic Forum. The company becomes a Partner Member Associate and will participate in the WEF System Initiative focused on Shaping the Future of Health and Healthcare. The initiative has a goal of transforming the continuum of care – from prevention to diagnosis, treatment,...

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:30

Ferring Pharmaceuticals appoints Sophie Opdyke to lead its new U.S. oncology division

PARSIPPANY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Ferring?src=hash" target="_blank"gt;#Ferringlt;/agt;--Sophie Opdyke, Pharm.D., MBA, will be responsible for building the Ferring Pharmaceuticals (U.S.) oncology division

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:25

InGeneron Expands Development Pipeline with Two Osteoarthritis Programs

HOUSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/backpain?src=hash" target="_blank"gt;#backpainlt;/agt;--InGeneron expands development pipeline with two studies for chronic backpain and wrist osteoarthritis, setting focus on orthopedic indications.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:00

BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source

PALO ALTO, Calif.--(BUSINESS WIRE)--BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR and Viking Global Investors. Other existing investors participating included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital; and they were joined by new investors Sequoia Capital, and a blue-chip long-term investor. The financing wil

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:00

Talee Bio Announces $4.5 Million Award from the Cystic Fibrosis Foundation to Advance Development of Two Gene Therapy Product Candidates

PHILADELPHIA--(BUSINESS WIRE)--Talee Bio, Inc., a development stage biopharmaceutical company focused on developing gene therapy treatments for cystic fibrosis, today announced agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL-101 and TL-102. The CF Foundation committed up to $4.5 million to expedite the development of both product candidates for all people with cystic fibrosis, and par

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company's board of directors. "We are extremely pleased to add these two experienced executives to Sage's board of directors. As Sage continues to advance its programs in development, adding an executive

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

Triumvira Announces Build out of Senior Management Team with Addition of Industry-Experienced Professionals in R&D and Business Development

AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira appoints Andreas Bader as Senior Vice President of Research & Development and Joshua Carle as Vice President of Business Development.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model

LOS ANGELES--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Breastfeeding?src=hash" target="_blank"gt;#Breastfeedinglt;/agt;--Supplementation with unique B3 vitamin nicotinamide riboside confers significant and enduring physiological benefits to mouse mothers and offspring.

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 13:30

Idiopathic Pulmonary Fibrosis Report - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Idiopathic Pulmonary Fibrosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Idiopathic Pulmonary Fibrosis . The report includes information of marketed products including their product des

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 13:24

EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL

The approval was based on data from the Phase 2 BLAST study in frontline and relapsed/refractory ALL, the largest prospective trial for MRD-positive ALL ever conducted. BLINCYTO, a The post EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease

RP-A501 is the Company's first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of The post Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

GSK closes acquisition of Tesaro for $5.1bn

Tesaro acquisition will enable GSK to strengthen its pharmaceutical business; and expand its pipeline and commercial capability in oncology. Tesaro president and COO Dr Mary Lynne Hedley said: The post GSK closes acquisition of Tesaro for $5.1bn appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Wed Jan 23, 2019 11:52

UroGen Pharma Announces Proposed Public Offering of Ordinary Shares

NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of ordinary shares sold in the offering at the pu

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 23:01

LabCorp Named to FORTUNE Magazine's 2019 List of 'World's Most Admired Companies,' Making the Annual List for the Second Consecutive Year

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2019 List of World's Most Admired Companies, making the annual list for the second consecutive year. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, is given to top executives, directors, and financial analysts to identify the companies that enjoy the strongest reputations within their indust

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 17:35

Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell and Be The Match BioTherapies® announced a collaboration to improve outcomes for patients undergoing bone marrow transplantation.

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:30

Bio-Thera Solutions Announces Initiation of Phase III Clinical Trial for BAT1806, a Proposed Biosimilar of Actemra® (Tocilizumab)

GUANGZHOU, China--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/arthritis?src=hash" target="_blank"gt;#arthritislt;/agt;--Bio-Thera Solutions announces the initiation of a Phase III clinical trial for BAT1806, a proposed biosimilar of Actemra® (Tocilizumab).

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:08

Remove ads

LabConnect Announces Global Sample Processing Network

SEATTLE--(BUSINESS WIRE)--LabConnect is pleased to announce a new service: LabConnect's global sample processing network (GSPN).

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, February 7, 20191:30 p.m. Pacific Time / 4

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Rainier Therapeutics Announces Oral Abstract Presentation on Fierce 21 Phase 2 Trial of Vofatamab in Metastatic Urothelial Cell Carcinoma (Bladder Cancer) at the 2019 ASCO Genitourinary Cancers Symposium

SAN LEANDRO, Calif.--(BUSINESS WIRE)--Data from ongoing P2 trial of Rainier's FGFR3-targeted antibody vofatamab to be presented at 2019 ASCO Genitourinary Cancers Symposium Feb 14 in SF

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Resumen: Gore presenta en Europa la endoprótesis para aorta torácica adaptable GORE® TAG® con perfiles reducidos

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) ha introducido hoy perfiles reducidos para los diámetros más utilizados de la endoprótesis para aorta torácica adaptable GORE® TAG® con el sistema de CONTROL ACTIVO. El perfil reducido permite a los médicos realizar reparaciones endovasculares torácicas (TEVAR) en pacientes con vasos más pequeños donde el acceso es difícil y la anatomía aórtica es tortuosa, lo que amplía la disponibilidad de la endoprótesis para aorta

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:47

Samenvatting: Gore introduceert GORE® TAG® Conformable Thoracic Stent Graft met gereduceerde profielen in Europa

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) introduceerde vandaag gereduceerde profielen voor de meest gebruikte diameters van de GORE® TAG® Conformable Thoracic Stent Graft met ACTIVE CONTROL System. Het gereduceerde profiel stelt artsen in staat om TEVAR uit te voeren bij patiënten met kleinere vaten waar de toegang moeilijk is en de aorta anatomie kronkelig is, waardoor de beschikbaarheid van Gore's thoracale stenttransplantaat wordt uitgebreid naar een groter

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:47

Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

WILMINGTON, Del.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24INCY&src=ctag" target="_blank"gt;$INCYlt;/agt;--Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:30

Data Presented at LINC Confirm the Safety and Effectiveness of Zilver® PTX®

BLOOMINGTON, Ind.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/cookmedical?src=hash" target="_blank"gt;#cookmedicallt;/agt;--Today at the Leipzig Interventional Course (LINC), Cook Medical participated in significant discussion about the use of paclitaxel to treat patients suffering from PAD. Through several presentations to meeting attendees, data supported the use of paclitaxel-coated devices to help the more than 200 million1 patients globally who are fighting the disease. "We believe...

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:10

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerate

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/AlopeciaAreata?src=hash" target="_blank"gt;#AlopeciaAreatalt;/agt;--Concert completed enrollment in its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata.

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Immunochina Raises $20.4 Million USD in Series C Financing

BEIJING--(BUSINESS WIRE)--Beijing-based Immunochina Pharmaceuticals today announced the closing of its $140 million RMB Series C financing (approximately $20.4 million in US Dollars). This financing will enable the company to expand its GMP-grade manufacturing capabilities while continuing clinical trials for its lead IM19 product targeting B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Non Hodgkin's Lymphoma, as well as advancing the development of its pipeline targeting multiple solid and li

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Aplastic Anemia - Pipeline Insight, 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Aplastic Anemia - Pipeline Insight, 2019" drug pipelines report has been added to ResearchAndMarkets.com's offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Aplastic Anemia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, assoc

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 13:40

Cluster Headache Syndrome - Pipeline Insight, 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cluster Headache Syndrome - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Cluster Headache Syndrome development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 13:34

TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products

GLASGOW, Scotland--(BUSINESS WIRE)--TC BioPharm (TCB), a developer of CAR-T immuno-oncology products, including Gamma Delta T (GDT) cell therapies, today announced it has completed formulation of its first allogeneic GDT cell banks. The T cell banks provide TCB with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different cancer types, both hematological and solid tumors. The project was supported by funding from the European Uni

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 12:55

Rationale and study design of the MyHEART study: A young adult hypertension self-management randomized controlled trial

Publication date: Available online 21 January 2019Source: Contemporary Clinical TrialsAuthor(s): Heather M. Johnson, Lisa Sullivan-Vedder, KyungMann Kim, Patrick E. McBride, Maureen A. Smith, Jamie N. LaMantia, Jennifer T. Fink, Megan R. Knutson Sinaise, Laura M. Zeller, Diane R. LauverAbstractYoung adults (18–39 year-olds) with hypertension have a higher lifetime risk for cardiovascular disease. However, less than 50% of young adults achieve hypertension control in the United States. Hypertension...

ScienceDirect Publication: Contemporary Clinical Trials

Tue Jan 22, 2019 13:13

EC approves Vertex's CF treatment Orkambi for children aged two to five years

The label extension has been granted to treat the most common form of CF based on data from a phase 3 open-label safety study in 60 patients. According The post EC approves Vertex's CF treatment Orkambi for children aged two to five years appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Nash's NASH NP-160 shows repeated positive results in second pre-clinical study

In addition, a second compound, NP-135 was identified as an additional lead. Both NP-135 and NP-160 are one of a number of already approved compounds that Nash has The post Nash's NASH NP-160 shows repeated positive results in second pre-clinical study appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Global Clinical Trials 2007-2018: Current Trends and Recent Advancements - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Clinical Trials - Current Trends and Recent Advancement" report has been added to ResearchAndMarkets.com's offering. "Global Clinical Trials Current Trends and Recent Advancement", provides an in-depth assessment of the current trends in the number of clinical trials globally, Top 10 therapy area, geography wise clinical trials, YOY clinical trials in top 10 therapy area. An overview of clinical guidelines reforms has also been provided to show how regulator

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 11:17

PredictImmune Confirms Canadian Patent Grant

CAMBRIDGE, England--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IBD?src=hash" target="_blank"gt;#IBDlt;/agt;--PredictImmune confirm Canadian patent grant which covers PredictImmune's intellectual property relating to methods for predicting autoimmune disease

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 11:00

PCI announces further investment in infrastructure for packaging of controlled substances

PCI has extended onsite controlled substance storage at its US commercial packaging locations in Philadelphia, PA and Rockford, IL, and will undertake further expansions as demand increases for The post PCI announces further investment in infrastructure for packaging of controlled substances appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Tue Jan 22, 2019 12:25

Remove ads

Wren Therapeutics Completes £18 Million Series A Financing

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Wren Therapeutics ("Wren"), a biopharmaceutical company focused on drug discovery and development for protein misfolding diseases, today announces it has completed a Series A financing round. The company, formally founded in 2016, raised a total of £18 million from an international syndicate led by The Baupost Group with participation from LifeForce Capital and a number of high net worth individual investors. Protein molecules form the machinery that

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 09:30

EMMAC Life Sciences PLC: Acquisition of a Majority Interest in Medalchemy, a GMP Certified Laboratory, in Alicante Spain

LONDON--(BUSINESS WIRE)--EMMAC, the European independent medical cannabis company, is pleased to announce the acquisition of a majority interest in Medalchemy, a fully-licensed GMP certified laboratory in Alicante, Spain. Medalchemy, a technology-based manufacturing company located on the premises of the University of Alicante, has more than a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs) and has submitted license applications to i

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 09:00

Updated Analysis of Pivotal Study Reveals: Proactive, High Dosage of Venofer® Significantly Reduces Risk of Death or Major Cardiovascular Events in Haemodialysis Patients

ZURICH--(BUSINESS WIRE)--Re-analysis of pivotal study reveals: Proactive, High DOSAGE OF venofer®...

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 08:00

Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women's health and gastroenterology. The collaboration brings together specialist expertise from Karolinska Institutet in early stage research, Rebiotix Inc. (acquired by Ferring in 2018), a late-stage clinical microbiome company, and Ferring's therapeutic area and co

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 08:00

Proteus Digital Health Launches Digital Oncology Medicines to Improve Patient Outcomes

January 17, 2019 – REDWOOD CITY, Calif. and MINNEAPOLIS, Minn. – Proteus Digital Health®, Inc., Fairview Health Services, and University of Minnesota Health announced today that for the first time cancer patients are using digital...

Drugs.com - Clinical Trials

Thu Jan 17, 2019 22:01

Two Positive Phase III studies of Tafenoquine for the Radical Cure of Plasmodium vivax Malaria Published in The New England Journal of Medicine

London UK; Philadelphia US; Geneva Switzerland - January 16, 2019 -- GSK and Medicines for Malaria Venture (MMV) today announced the publication of positive results from two phase III studies of single-dose tafenoquine for the radical cure...

Drugs.com - Clinical Trials

Wed Jan 16, 2019 23:01

vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study

HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small...

Drugs.com - Clinical Trials

Wed Jan 16, 2019 22:01

Amgen Makes All Repatha (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at...

Drugs.com - Clinical Trials

Mon Jan 07, 2019 22:01

Gore führt GORE® TAG® Conformable Thoracic Stent Graft mit reduzierten Profilen für die Vermarktung in Europa ein

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) meldete heute die Markteinführung reduzierter Profile für die am häufigsten verwendeten Durchmesser von GORE® TAG® Conformable Thoracic Stent Graft mit ACTIVE CONTROL System. Das reduzierte Profil ermöglicht es den Ärzten, bei Patienten mit kleineren Blutgefäßen eine thorakale endovaskuläre Aortenreparatur (TEVAR) durchzuführen, wenn der Zugang anspruchsvoll und die Aorta gewunden ist, um auf diese Weise die Einsatzmö

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 22:37

Gore lance sur le marché européen GORE® TAG®, une endoprothèse thoracique conformable à profils réduits

FLAGSTAFF, Arizona--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) a présenté aujourd'hui des profils réduits des diamètres les plus couramment utilisés de l'endoprothèse thoracique conformable implantable GORE® TAG® dotée du système ACTIVE CONTROL. La réduction du profil permet aux médecins de procéder à une procédure TEVAR (réparation endovasculaire des anévrismes de l'aorte thoracique) chez les patients dont les vaisseaux sont étroits et difficiles d'accès et l'anatomie aortique t

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 19:30

Riassunto: Gore lancia in Europa lo stent graft toracico conformabile GORE® TAG® con profili ridotti

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) ha oggi lanciato profili ridotti per i diametri più comunemente utilizzati dello stent graft toracico conformabile GORE® TAG® con sistema ACTIVE CONTROL. Il profilo ridotto consente al personale medico di eseguire trattamenti endovascolari dell'aorta toracica (TEVAR) nei pazienti con vasi sanguigni più piccoli, di difficile accesso e con anatomia aortica tortuosa, ampliando la disponibilità dello stent graft toracico di

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 16:18

Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 14:00

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. "Today's approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF," said Reshma K

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 11:00

Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 10:00

Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism

Promentis is developing SXC-2023 along with other compounds that engage System xc-, a central nervous system target addressing glutamatergic imbalance and oxidative stress, to treat trichotillomania and other The post Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 12:58

Kyn Therapeutics, Celgene partner on immuno-oncology therapies development

The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet The post Kyn Therapeutics, Celgene partner on immuno-oncology therapies development appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 09:02

Lilly's second immune-oncology candidate using Zymeworks' Azymetric platform to start clinical trials

In accordance with Zymeworks' 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly's submission of an IND application for The post Lilly's second immune-oncology candidate using Zymeworks' Azymetric platform to start clinical trials appeared first on Pharmaceutical Business review.

PBR - Clinical Trials News

Mon Jan 21, 2019 12:58

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

TOKYO--(BUSINESS WIRE)--At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the "Company") resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the "Group" refers to two companies, SanBio Co., Ltd., and SanBio, Inc.) 1. Details of the Decision As part of its mission to introduce new therapeutic drugs for the central nervous system,

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 02:05

Design of a randomized trial testing a multi-level weight-control intervention to reduce obesity and related health conditions in low-income workers

Publication date: Available online 19 January 2019Source: Contemporary Clinical TrialsAuthor(s): Richard I. Stein, Jaime R. Strickland, Rachel G. Tabak, Ann Marie Dale, Graham A. Colditz, Bradley A. EvanoffAbstractWeight-control is a major public health focus for preventing multiple obesity-related health conditions. While clinic-based intensive lifestyle interventions are successful, low-socioeconomic-status (SES) populations, which have a higher burden of obesity, are difficult to reach; thus,...

ScienceDirect Publication: Contemporary Clinical Trials

Sun Jan 20, 2019 13:44